PE20221259A1 - Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras - Google Patents

Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras

Info

Publication number
PE20221259A1
PE20221259A1 PE2022000810A PE2022000810A PE20221259A1 PE 20221259 A1 PE20221259 A1 PE 20221259A1 PE 2022000810 A PE2022000810 A PE 2022000810A PE 2022000810 A PE2022000810 A PE 2022000810A PE 20221259 A1 PE20221259 A1 PE 20221259A1
Authority
PE
Peru
Prior art keywords
drug
preparation
treatment against
against tumors
nras mutation
Prior art date
Application number
PE2022000810A
Other languages
English (en)
Inventor
Zaiqi Wang
Jiangwei Zhang
Jun Jiang
Original Assignee
Inxmed Nanjing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inxmed Nanjing Co Ltd filed Critical Inxmed Nanjing Co Ltd
Publication of PE20221259A1 publication Critical patent/PE20221259A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere al compuesto defactinib, tambien conocido como BI853520, GSK2256098, PF-00562271 y VS-4718, o una sal aceptable del mismo. Tambien se refiere a una combinacion del compuesto defactinib con un segundo agente terapeutico, tal como nimustina, carmustina, entre otros. Dicho compuesto es un inhibidor de la proteina tirosina cinasa 2 (PTK2 o FAK), siendo util en el tratamiento de un tumor que tiene una mutacion del oncogen NRAS.
PE2022000810A 2019-11-18 2020-11-17 Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras PE20221259A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911128794 2019-11-18
PCT/CN2020/129350 WO2021098679A1 (zh) 2019-11-18 2020-11-17 Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途

Publications (1)

Publication Number Publication Date
PE20221259A1 true PE20221259A1 (es) 2022-08-16

Family

ID=75981319

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000810A PE20221259A1 (es) 2019-11-18 2020-11-17 Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras

Country Status (11)

Country Link
US (2) US20230145356A1 (es)
EP (1) EP4062914A4 (es)
JP (1) JP2023503897A (es)
KR (1) KR20220101677A (es)
CN (1) CN114667144A (es)
AU (1) AU2020388848A1 (es)
BR (1) BR112022009571A2 (es)
CA (1) CA3158585A1 (es)
MX (1) MX2022005994A (es)
PE (1) PE20221259A1 (es)
WO (1) WO2021098679A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114728005A (zh) * 2019-11-28 2022-07-08 应世生物科技(南京)有限公司 Bi853520在癌症治疗中的用途
BR112022015150A2 (pt) * 2020-02-05 2022-10-11 Inxmed Nanjing Co Ltd Combinação de bi853520 com fármacos quimioterápicos
PE20231303A1 (es) 2020-08-03 2023-08-24 Inxmed Nanjing Co Ltd Forma solida de compuesto
WO2023020291A1 (zh) 2021-08-16 2023-02-23 应世生物科技(南京)有限公司 In10018与pld的联用
CN113855695B (zh) * 2021-11-01 2023-06-06 上海理工大学 一种结肠释药口服复方药物组合物及其制备方法
TW202339755A (zh) * 2021-12-10 2023-10-16 大陸商應世生物科技（南京）有限公司 治療腫瘤的藥物組合及用途
CN114681471B (zh) * 2022-01-19 2023-06-06 杭州师范大学 一种硼替佐米和榄香烯分子配伍药物组合及其应用
WO2023138630A1 (zh) * 2022-01-21 2023-07-27 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
WO2023193705A1 (zh) * 2022-04-07 2023-10-12 深圳微芯生物科技股份有限公司 西奥罗尼在抗胰腺癌中的用途
WO2023246869A1 (zh) * 2022-06-24 2023-12-28 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物
WO2024041527A1 (zh) * 2022-08-24 2024-02-29 应世生物科技(南京)有限公司 Fak抑制剂及微管抑制剂的药物组合及用途
TW202410898A (zh) * 2022-09-05 2024-03-16 大陸商應世生物科技（南京）有限公司 Fak抑制劑及egfr-tki的藥物組合及用途
WO2024067631A1 (zh) * 2022-09-30 2024-04-04 应世生物科技(南京)有限公司 Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途
WO2024140295A1 (zh) * 2022-12-28 2024-07-04 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI491605B (zh) * 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
FI3698790T3 (fi) * 2014-02-07 2023-06-06 Verastem Inc Menetelmiä epänormaalin solukasvun hoitamiseksi
US10532056B2 (en) * 2015-06-29 2020-01-14 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
JP2022547358A (ja) * 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
BR112022015150A2 (pt) * 2020-02-05 2022-10-11 Inxmed Nanjing Co Ltd Combinação de bi853520 com fármacos quimioterápicos

Also Published As

Publication number Publication date
EP4062914A4 (en) 2024-01-17
CA3158585A1 (en) 2021-05-27
WO2021098679A1 (zh) 2021-05-27
US20230145356A1 (en) 2023-05-11
JP2023503897A (ja) 2023-02-01
BR112022009571A2 (pt) 2022-08-02
MX2022005994A (es) 2022-06-17
CN114667144A (zh) 2022-06-24
EP4062914A1 (en) 2022-09-28
KR20220101677A (ko) 2022-07-19
US20230364088A1 (en) 2023-11-16
AU2020388848A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
PE20221259A1 (es) Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CL2019003091A1 (es) Terapia de combinación.
CO2018012482A2 (es) Formulaciones de un inhibidor de lsd1
CL2016002900A1 (es) Compuesto 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoxietil)pirrolidin-3-ll)-3-(4-metil-3-(2- metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)urea, inhibidor de trka cinasa; proceso para prepararlo; composición farmacéutica que lo comprende; y uso para tratar dolor, cáncer, inflamación, enfermedades neurodegenerativas, entre otros.
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
PH12018500642A1 (en) Anti-garp antibody
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
PE20230180A1 (es) Uso de bi853520 en tratamiento contra el cancer
CL2022003733A1 (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
MX2018005256A (es) Formulaciones inyectables de toxina botulinica y metodos de uso de las mismas que tienen efecto terapautico o cosmetico de larga duracion.
PH12021550992A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
CO2023018231A2 (es) Restos de administración terapéutica novedosos y usos de estos
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
BR112020019875A8 (pt) composições tópicas para alívio da dor
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
AR112284A1 (es) Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico
PH12020550821A1 (en) Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
CL2021002533A1 (es) Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras
CO2022002731A2 (es) Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
CL2023001062A1 (es) Compuestos fosfolípidos y usos de estos
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody